NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $162.71 -0.52 (-0.32%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Charles River Laboratories International Stock (NYSE:CRL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CRL alerts:Sign Up Key Stats Today's Range$162.15▼$165.2250-Day Range$147.37▼$179.1052-Week Range$91.86▼$230.02Volume260,385 shsAverage Volume1.24 million shsMarket Capitalization$8.01 billionP/E RatioN/ADividend YieldN/APrice Target$175.69Consensus RatingHold Company Overview Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Read More Charles River Laboratories International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreCRL MarketRank™: Charles River Laboratories International scored higher than 82% of companies evaluated by MarketBeat, and ranked 195th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingHold Consensus RatingCharles River Laboratories International has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 5 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageCharles River Laboratories International has only been the subject of 4 research reports in the past 90 days.Read more about Charles River Laboratories International's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth17.52% Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 17.52% in the coming year, from $9.36 to $11.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is -122.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is -122.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 5.20. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.50% of the float of Charles River Laboratories International has been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently decreased by 5.60%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.55 Percentage of Shares Shorted4.50% of the float of Charles River Laboratories International has been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently decreased by 5.60%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.35 News SentimentCharles River Laboratories International has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Charles River Laboratories International this week, compared to 15 articles on an average week.Search Interest2 people have searched for CRL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $186,096.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRL Stock News HeadlinesInsider Selling: Charles River Laboratories International (NYSE:CRL) EVP Sells 800 Shares of StockAugust 21, 2025 | insidertrades.comCharles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume Sells 400 SharesAugust 9, 2025 | insidertrades.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 29 at 2:00 AM | Brownstone Research (Ad)Charles River Laboratories Stock: Analyst Estimates & RatingsAugust 27 at 12:55 AM | msn.comCharles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of "Hold" by AnalystsAugust 26 at 2:47 AM | americanbankingnews.comCharles River Laboratories International Inc. stock underperforms Thursday when compared to competitorsAugust 22, 2025 | msn.comInsider Sell: Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL)August 20, 2025 | gurufocus.comCharles River Laboratories International (NYSE:CRL) Downgraded by Wall Street Zen to "Buy"August 19, 2025 | americanbankingnews.comSee More Headlines CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $184.60 at the beginning of 2025. Since then, CRL shares have decreased by 11.9% and is now trading at $162.6250. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) posted its quarterly earnings data on Wednesday, August, 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The firm's revenue was up .6% compared to the same quarter last year. Read the conference call transcript. Is Charles River Laboratories International buying back stock? Charles River Laboratories International's Board of Directors approved a share buyback plan on Wednesday, August 7th 2024, which allows the company to buy back $1,000,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued. Does Charles River Laboratories International have any subsidiaries? Charles River Laboratories International subsidiaries include Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and more. Who are Charles River Laboratories International's major shareholders? Top institutional shareholders of Charles River Laboratories International include Allspring Global Investments Holdings LLC (4.66%), State Street Corp (3.78%), Ariel Investments LLC (2.88%) and Invesco Ltd. (2.51%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Richard F Wallman, Michael Gunnar Knell, George Massaro and Shannon M Parisotto. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Home Depot (HD) and Alphabet (GOOG). Company Calendar Last Earnings8/06/2025Today8/29/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees20,100Year Founded1947Price Target and Rating Average Price Target for Charles River Laboratories International$175.69 High Price Target$210.00 Low Price Target$140.00 Potential Upside/Downside+7.5%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.33) Trailing P/E RatioN/A Forward P/E Ratio17.47 P/E Growth5.2Net Income$22.20 million Net Margins-1.69% Pretax Margin-0.45% Return on Equity15.74% Return on Assets7.09% Debt Debt-to-Equity Ratio0.69 Current Ratio1.36 Quick Ratio1.10 Sales & Book Value Annual Sales$4.03 billion Price / Sales2.00 Cash Flow$21.80 per share Price / Cash Flow7.50 Book Value$68.26 per share Price / Book2.39Miscellaneous Outstanding Shares49,214,000Free Float48,574,000Market Cap$8.05 billion OptionableOptionable Beta1.48 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NYSE:CRL) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.